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INTRODUCTION 
Irritable bowel syndrome (IBS) is the most commonly recognized gastrointestinal diagnosis 
worldwide.1,2 IBS is part of a set of gastrointestinal disorders previously called functional gastrointestinal 
disorders (FGIDs) and now referred to as disorders of gut-brain interaction (DGBIs) by the Rome 
Foundation, referring to their proposed pathophysiology.2,3 IBS affects roughly 11% of the population 
and has a large financial impact, with estimates of the US burden of indirect costs totaling at up to $20 
billion, or over $7,000 per year per patient with IBS.4 
 
IBS not only has an economic burden but also has a significant impact on quality of life on the 
people it affects.5,6 Patients with diarrhea-predominant and mixed subtypes (IBS-D and IBS-M, discussed 
in further detail below) tend to report poorer quality of life than patients with constipation-predominant 
IBS (IBS-C) due to increased food avoidance and urgency of bowel movements affecting social 
situations.6 In one cross-sectional survey, respondents with IBS-D reported their work productivity being 
affected for nine days per month, on average, and missing two work days per month due to their 
symptoms. Additionally, respondents with IBS-D experienced more impact on daily activities.4 This 
impact on quality of life and productivity can be managed with effective treatment methods that 
address the underlying cause of symptoms. 
 
Given the abundance of studies related to IBS, its multi-factorial pathogenesis, and its various 
treatment modalities, a comprehensive analysis of all subtypes of IBS is beyond the scope of this review. 
Therefore, focus will be largely given to the IBS-D subtype with brief mentions of IBS-C as a comparison 
method. IBS-D presents the largest clinical challenges with a lack of consensus on the pathophysiology 
of the condition and thus more possibilities in treatment modalities. This paper will review the clinical 
presentation of IBS-D, describe the proposed pathophysiology of the condition, and discuss current 
treatment modalities, questioning whether these treatments address the underlying cause of the 
disease and whether the course of treatment will improve quality of life in the patient. The goal of 
treatment in any condition is to improve quality of life in the patient, and historic methods of substantial 
food restriction and polypharmacy in IBS patients may not be the best approach. Finally, this paper will 
present recommendations for the best approach for IBS from a dietetics perspective. 
 
EPIDEMIOLOGY 
Estimating the incidence and prevalence of IBS and its subtypes is challenging due to the nature 
of the disease and the fact that it can spontaneously resolve or switch subtypes.7 The population 
prevalence of IBS has been estimated by many studies, but the generally agreed upon prevalence is 
around 11% of the North American population.6,8 The worldwide prevalence varies between 9-23%.5 
Though incidence of IBS is not widely reported worldwide, there are some long-term studies in the US 
that have estimated an incidence rate of 1-2%.6 The IBS-D subtype represents about one-third of the 
population with IBS according to current estimates6, but better classification of subtypes would improve 
the accuracy of IBS numbers.  
 
IBS has been added to the most recent edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) as a somatic symptom disorder, in which the patient has a large mental focus 
on their physical symptoms that cause severe emotional or mental distress. Prior to its inclusion into the 
fifth version of the DSM, patients seeing psychiatrists with symptoms of IBS commonly remained 
undiagnosed.6 IBS is sorted into its subtypes for diagnosis: IBS-D (IBS with diarrhea predominating), IBS-C 
(IBS with constipation predominating), and IBS-M or IBS-A (IBS with mixed or alternating bowel 
patterns).5 
 
IBS is more frequent in women than men, estimated at an odds ratio of 1.67 (95% CI: 1.53-1.82) 
by one meta-analysis of 56 studies.9 However, the ratio of gender across subtypes is not evenly 
distributed. The same meta-analysis found that women are more likely to develop IBS-C (OR 2.38, 95% 
CI: 1.45-3.92) than IBS-D (OR 0.45, 95% CI: 0.32-0.65). The pooled prevalence of IBS-C in women in this 
study was 40% (95% CI: 30-51%) while the pooled prevalence of IBS-D in women was 31% (95% CI: 22-
41%).9  
 
One proposed theory for the etiology of IBS, discussed in further detail in the Pathophysiology 
section, is development of symptoms after an enteric or non-enteric infection that required the use of 
antibiotics. Indeed, the risk of IBS post-infection is high according to a meta-analysis, with an estimated 
pooled odds ratio of 7.3 (95% CI: 4.7-11.1) for the development of IBS after gastroenteritis.6 
 
DIAGNOSIS 
 The diagnosis of irritable bowel syndrome follows a systematic process (Figure 1) when properly 
addressed and recognized by health care providers. Due to the wide ranging symptoms, that are not all 
enteric in nature, and the variance of symptom severity between patients, many patients will seek out 
treatment from a variety of providers with specialties other than gastroenterology and thus, the 
condition may be treated with symptom management rather than addressed as a whole.5 Additionally, 
there is a lack of consensus amongst physicians of varying specialties that IBS is a true diagnosis rather 
than a combination of other diseases that create this particular set of symptoms.1 Some clinicians 
choose to diagnose IBS through excluding all other options first, but the gold standard for diagnosis 
remains to utilize the Rome criteria, as will be described in detail below.6,7  
 
Figure 1. The process of diagnosing IBS and other FGIDs includes ruling out other possible diagnoses through physical exams, 
potential blood or procedural testing, and a careful review of symptoms against a validated set of criteria.  
 
Symptoms 
Irritable bowel syndrome is a heterogenous condition that is characterized by wide-ranging 
symptoms that can present differently in each patient. The severity of symptoms varies between 
patients and can even shift over time in a single patient, contributing to the difficulty in diagnosis. The 
impact on quality of life and the type of symptoms may prompt patients to initially seek out various 
types of health care providers, but IBS is the most common reason for referrals to gastroenterology 
clinics.1 
 
A physical examination is part of the recommended protocol for diagnosing IBS. A lack of 
significant findings, such as an abdominal mass or enlarged lymph nodes, on physical examination 
supports the diagnosis for IBS and can rule out other possible disease states.6 An exam or history that 
reveals any of several alarm features, such as bloody stool, anemia, or unexplained weight loss, should 
prompt further investigation into these symptoms before a diagnosis of IBS is given, even if the 
diagnostic criteria are met. IBS is more common in patients under 50 years, and symptoms in patients 
older than 50 may be indicative of other disease states and could elicit further testing.1,6,8 
 
Gastrointestinal and other symptoms are collected and judged against a set of criteria 
developed by the Rome Foundation for diagnosis of IBS or other functional bowel disorders. The Rome 
IV criteria, discussed in further detail below, uses a defined set of GI symptoms to differentiate between 
DBGIs. The multifactorial pathogenesis of IBS is complex and not completely understood. The factors 
that are considered contributory to symptom presentation and severity are: motility disturbance, 
visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered 
central nervous system (CNS) processing.10 Keeping in consideration the underlying cause(s) of IBS could 
lead to safe and effective treatment of this disease and improve the quality of life in those that it affects. 
 
Alarm Features 
A thorough history of the patient should be collected by the health care provider to ascertain if 
any symptoms exist that may be indicative of a more severe disease. Symptoms such as iron-deficiency 
anemia, unexplained weight loss, bloody stool, rectal bleeding, diarrhea in large volumes, nocturnal 
diarrhea, and greasy stools are not associated with IBS and should elicit further testing before 
considering IBS as a potential diagnosis.1,8 Additionally, family history of colorectal cancer or 
Inflammatory Bowel Diseases (IBD), such as Crohn’s Disease or Ulcerative Colitis, or the presence of 
ascites, hepatomegaly, splenomegaly, or any abdominal mass, warrants further investigation.8 
 
If any alarm symptoms exist, a colonoscopy may be warranted to exclude IBD or malignancy as a 
possible explanation.1,6 Additionally, if the patient is older than 50 years, a colonoscopy is suggested per 
national recommendations, even in the absence of any alarm features.8 
 
Rome Criteria for Diagnosis of IBS 
There are currently no validated biomarkers for the diagnosis of IBS.1,6 Thus, a set of criteria for 
diagnosis of IBS and distinguishing between subsets of IBS have been developed and updated over the 
past several decades. Diagnosis of IBS is comprised entirely by symptoms – no laboratory or other 
physical findings are required to fulfill diagnostic criteria for IBS.2 The first set of IBS diagnostic criteria 
was developed by Manning, et al, in 1979. Symptoms were described but no duration or timing of 
symptoms were specified by this criteria.5 The current gold standard is the Rome criteria, which was first 
described in 1989 and is now on its fourth version, released in 2016.2,5 
 
Previous versions of the Rome criteria (versions I – III) differentiated between IBS-D and 
functional diarrhea as separate entities, depending on the level of pain experienced by the patient. 
Functional diarrhea has many of the same diagnostic criteria as IBS-D (Figure 2), but patients may not 
experience abdominal pain/bloating or it may be not be a predominant symptom as it is in IBS-D.11 In 
the most recent update, the model describes functional bowel disorders as a continuum rather than 
independent disease states (Figure 3). The most recent version of the Rome criteria8 (Figure 2) 
eliminates the word ‘discomfort’ from the set of symptoms, as this is not a universally recognized term 
in all cultures and languages and was difficult to define.2,3 Additionally, the frequency threshold of 
symptoms was the other major change made in the Rome IV criteria. 
 
 
Rome IV Diagnostic Criteria for Irritable Bowel Syndrome8 
Recurrent abdominal pain, on average, at least one day per week over the last three months, with at least two 
of the following: 
• Related to defecation 
• Associated with a change in frequency of stool 
• Associated with a change in form (appearance) of stool 
 
Criteria must be fulfilled over the last three months with symptom onset at least six months prior to diagnosis. 
Figure 2. Diagnostic criteria for IBS. Information adapted from Lacy, et al, 2016. 
 
 
Figure 3. The most recent Rome IV criteria have changed 
their definition of DBGIs from discrete conditions to a set 
of symptoms that exist on a continuum. IBS is just one of 
these disorders and the range of symptoms of can shift an 
IBS diagnosis to the less-severe Functional Constipation 
(FC) or Functional Diarrhea (FD) with a reduction in pain 
symptoms.2 Image taken from Schmulson, et al, 2017. 
Figure 4. Bristol Stool Chart. Stool forms are characterized by 
their texture and shape and used to classify bowel habits in IBS 
subtype diagnosis. Image originally published in Lewis, 1997.12 
 
The Rome IV criteria also utilizes the Bristol Stool Scale (Figure 4) to classify bowel function and 
differentiate between subsets of IBS, with bowel habit definition based upon the days when there is at 
least one abnormal bowel movement. The criteria for the IBS-D subtype8 is as follows:  
- More than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7 and less 
than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2.  
- Alternative verbiage: “Patient reports that abnormal bowel movements are usually diarrhea” 
 
Though there is no consensus on the specificity and sensitivity of the Rome IV criteria, studies 
have shown that there is no significant difference in these measures between the Manning, Rome I, and 
Rome II criteria and all are validated to diagnose IBS and its subsets.5 However, the first population-
based study on IBS using Rome IV criteria saw a reduction by half in the prevalence of IBS when 
compared to Rome III criteria,2 suggesting that the new criteria may have better sensitivity and 
specificity. Another validation study found that the specificity of the Rome IV criteria was 97.1%.3 
Further population-based studies across varying cultures will provide better information on the accuracy 
of the Rome IV criteria.  
 
Differential Diagnoses 
The diagnostic criteria for IBS should be used carefully and systematically to avoid misdiagnosing 
or over-diagnosing IBS. There is some overlap of symptoms between IBS and inflammatory bowel 
diseases, and many patients with IBD may fulfill the criteria for IBS.6,7 However, one prospective study 
with 900 subjects found that less than 1% of IBS patients without constipation, and none of the controls, 
had a positive diagnosis of IBD, and thus routine colonoscopy in IBS patients is not suggested.7 Instead, 
biomarkers such as C-reactive protein and fecal calprotectin may be used to exclude inflammation as a 
possible source of symptoms.7 A CRP level <0.5 mg/dl or fecal calprotectin levels <40 ug/g can be used 
to exclude IBD in patients with IBS symptoms.6,7  
 
The literature does suggest that patients with IBS symptoms are four times more likely to have a 
positive diagnosis for celiac disease. Testing for celiac disease should be considered in patients with the 
IBS-D subtype especially.  
 
Routine laboratory tests may be preferred by some providers, but patients with diagnosed IBS 
tend to have normal lab results as compared to patients with other diseases, such as Celiac or IBD, so a 
laboratory test may be more useful in excluding other diseases rather than diagnosing IBS.6 Results such 
as anemia or an elevated white blood cell count may indicate the presence of other conditions.8 Some 
other tests that may be indicated include: a basic metabolic panel (BMP) or complete metabolic panel 
(CMP), C-reactive protein (CRP), fecal calprotectin, thyroid panels, and stool analyses for bacterial 
infections.6 Testing for parasites should be considered only if the patient resides in or has recently 
visited developing countries.1 The literature recommends against testing for Small Intestinal Bacterial 
Overgrowth (SIBO) in IBS patients as a routine test, as there is not enough evidence to suggest a link 
between IBS and SIBO.1,5,6 
 
When the Rome criteria for diagnosis of IBS is met without additional alarm features in the 
patient, the overall recommendation is not to pursue further invasive testing.5,6 The risk of invasive 
testing, such as colonoscopy, does not outweigh the benefits, as the literature shows that the majority 
of patients do not have IBD or other conditions that would be detected by further workup.1 
 
Common Comorbidities 
The diagnosis of IBS-D often coincides with other comorbidities as the pathophysiology of these 
disorders can be similar to that of IBS.1,7 Gastrointestinal disorders such as gastroesophageal reflux 
disease (GERD) and functional dyspepsia, pelvic/urinary disorders such as prostatitis and hyperactive 
bladder, psychiatric disorders such as depression and anxiety, and somatic disorders such as 
fibromyalgia and chronic fatigue syndrome often occur alongside IBS.5,6  
 
Some studies exist that suggest a link between SIBO and IBS, considering whether an 
overgrowth of bacteria into the small intestine may elicit some of the symptoms of IBS. However, there 
is insufficient evidence in the literature about SIBO being a causative factor in IBS, as mentioned above. 
There are other explanations for IBS symptoms that extend beyond bacterial overgrowth, such as food 
sensitivities, alterations in neurotransmitter function, and infection- or antibiotic-related dysbiosis, 
which will all be described below. Treatments that are often successful at addressing IBS symptoms do 
not always address SIBO, which contradicts the evidence that SIBO is a causative factor of IBS 
symptoms.5 Thus, consideration and testing for SIBO in the process of diagnosis of IBS should be 




Post-infectious IBS (PI-IBS) refers to the development of IBS symptoms after an occurrence of 
gastroenteritis, or an infection within the GI tract. Infections can be viral or bacterial in nature but a 
prior episode of GI infection seems to be associated with increased risk for the development of IBS.13 
One study found a pooled odds ratio of 7.3 (95% CI: 4.7-11.1) for the development of IBS after an 
episode of gastroenteritis.6 Risk factors for PI-IBS include younger age, psychological conditions, and 
severity of the infection.1,6 PI-IBS has been known to spontaneously resolve or reduce in severity after a 
time period of about 6-8 years post-infection.7 
 
Clostridium difficile (C. diff) infection (CDI) incidence has grown over the last decade. Risk factors 
for CDI include older age (>65 years), antibiotics, and inpatient hospitalization. Community acquired CDI 
represents about 20-40% of C. diff infections. Wadhwa, et al, conducted a cross-sectional study in which 
205 patients with past CDI but no IBS completed a symptoms survey and found that, six months after 
infection, 25% of patients met Rome criteria for IBS.14  Of these patients, 52% met criteria for IBS-M, 
40% met criteria for IBS-D, and 4% met criteria for each IBS-C and IBS-U (IBS-Undifferentiated, a subtype 
that is used when bowel habits do not meet other subtype criteria but all other diagnostic criteria are 
met15).14 Risk for development of PI-IBS in this population included CDI lasting greater than 7 days, 
reaching statistical significance in this study for correlation with development of PI-IBS. Post-infectious 
IBS can present similarly to a recurrence of CDI, which could lead to an unnecessary course of antibiotic 
treatment. Frequent use of antibiotics then worsens the risk for recurrent C. diff infections.14 
 
Antibiotic Use 
The gut microbiota is a complex community of microorganisms in the small and large intestines 
that, with a healthy diversity and concentration of microbes, exist in a symbiotic relationship with the 
patient to create normal gut function. Antibiotic use may alter the gut microbiota or alter the release of 
cytokines, leading to an inflammatory response and development of IBS symptoms. The gut microbiota 
is typically abnormal in IBS patients (discussed in further detail below) and antibiotic use may contribute 
to one source of alteration of the microbiota.16 The effect of absorbable, broad-spectrum antibiotics on 
the development of IBS symptoms should not be confused with nonabsorbable antibiotics such as 
rifaximin that only act locally within the GI tract, which will be discussed in the following section on 
treatment of IBS.16 
 
Patients who have taken absorbable antibiotics for nonenteric infections may be more at risk for 
development of IBS and other FGIDs, according to a study by Paula, et al.16 This case-control study found 
that patients who have taken antibiotics are more likely to develop FGIDs than those who have not 
taken systemic antibiotics (OR 1.90, 95% CI: 1.21-2.98). In this study, 83% of cases (those that developed 
a FGID) had experienced a non-enteric infection that was treated with an antibiotic. One limitation of 
this study is the long period of time between the initial and follow-up surveys, making it impossible to 
establish a temporal relationship between antibiotics and development of IBS, but there still may be 
some connection between systemic antibiotic use and post-infection IBS.16  
 
Nutrient Sensitivities 
 Food allergies or sensitivities have been one commonly implicated cause of IBS symptoms and 
have been the subject of many studies in describing the pathophysiology of IBS. True food allergies are 
immune-modulated reactions that involve activation of immune cells (T cells) and release of 
immunoglobulins (IgE-mediated reactions). There is also a difference between a food intolerance and a 
food sensitivity. An intolerance refers to the body’s inability to digest, absorb, or metabolize a specific 
nutrient, such as lactose intolerance secondary to a deficiency in the enzyme lactase, or overreaction to 
fermentable carbohydrates. The symptoms of intolerances are mostly GI in nature and are likely 
secondary to the fermentation of these nutrients and development of excess gas by gut microbes. 
Alternatively, a sensitivity has both GI and non-GI symptoms that are immune modulated and operate 
on a dose-response relationship.17 Though food allergies are uncommon in IBS patients, many 
experience intolerances that respond to dietary exclusion with an improvement in symptoms.7 
 
 Wheat allergy and celiac disease are immune responses versus autoimmune reactions, 
respectively. A wheat allergy is an immune (IgE, IgA, or IgG) reaction to the proteins in wheat, namely 
gluten and gliadin, while celiac disease is characterized by the presence of anti-tissue transglutaminase 
(TG2) antibodies in response to ingestion of gluten, specifically.13 In contrast, a new term has been 
created to describe a non-immune response to wheat-containing foods, called nonceliac gluten 
sensitivity (NCGS).17 NCGS is unlike celiac disease or wheat allergy in that patients do not develop the 
same antibodies as patients with celiac disease or have the same immune response as patients with 
wheat allergy, but still respond symptomatically to a wheat- or gluten-free diet.13,17  
 
The symptoms of NCGS have both GI and non-GI presentations.13,17 GI symptoms of nonceliac 
gluten sensitivity are very similar to IBS symptoms, especially those in the IBS-D subtype. These include 
abdominal pain, bloating, and abnormal bowel function consisting of frequent, liquid stools. Thus, some 
have suggested that IBS symptomology can be attributed to a sensitivity to wheat or gluten. However, 
the extraintestinal symptoms of NCGS are unlike IBS, in that patients also have reported experiencing 
headaches, fatigue, joint pain, anemia, or depression.13 The most likely explanation for the overlap in 
symptoms is that a subset of IBS patients, and most frequently IBS-D patients, may also have NCGS, but 
NCGS is not the cause of IBS. An exclusion diet, as detailed in a following section, to determine the 
specific triggers of IBS symptoms would benefit patients with IBS to avoid over-restriction of foods and 
improve food-related quality of life. 
 
Carbohydrate intake, in some patients, can exacerbate IBS symptoms of abdominal pain, 
bloating, and excess gas.5 Some carbohydrates are fermented by gut bacteria to produce short chain 
fatty acids (SCFAs), which provide a source of energy to the gut epithelium and contribute to anti-
inflammatory and metabolic pathways. These carbohydrates are fermentable oligo-, di-, and 
monosaccharides and polyols (FODMAPs). IBS patients may be more sensitive to FODMAPs and may 
experience an increase in flatulence, leading to abdominal pain or potential increase in motility. One 
proposed mechanism for this sensitivity may be to an excess of gas-producing bacteria and/or a 
deficiency of gas-utilizing bacteria.6 
 
Self-reported lactose intolerance is seen in higher rates in patients with IBS than the general 
population. However, studies have shown that many patients with IBS will not have a positive result 
from hydrogen breath tests for lactose intolerance.1,5,6 One proposed mechanism behind the 
commonality of lactose intolerance symptoms among IBS patients is the increased fermentation of 
lactose by gut bacteria in an altered microbiota. 
 
Epithelial Barrier 
 The gut epithelium acts as a barrier between the gut lumen and the underlying tissue and 
circulatory system. The single-cell thick layer has tight junctions, held together by proteins, between 
cells to maintain the integrity of the barrier. Enlarged spaces between the epithelial cells of the gut 
mucosa may contribute to early symptomatic responses in IBS. It has been shown that IBS patients, 
regardless of the subtype, often have defects in epithelial permeability and an increase in immune 
responses to food ingestion.18 
 
The increase in permeability between epithelial cells allows immune cells to enter the gut 
mucosa, as well as macromolecules to exit the lumen before being properly digested. Tight junction 
changes have been found in biopsies in PI-IBS and especially in IBS-D. These degradations may occur due 
to infection by pathogens, as a reaction to alterations in the gut microbiota, or may be secondary to 
inflammatory processes.6  
 
Inflammatory response to immune cell infiltration of the epithelium could stimulate afferent 
nerves and contribute to visceral pain.1 One study performed food challenges in patients that reported 
gluten sensitivity at baseline, inspecting the intestinal epithelium with endomicroscopy after ingestion of 
gluten. The researchers found breaks in tight junctions and immune cell infiltration of the gut epithelial 
wall within minutes of the food challenge, suggesting that food sensitivities may contribute to defects in 
the epithelial wall, or ‘leaky gut’.17  
 
 
Inflammation and Immune Reactions 
The gut microbiota has a wide variety of functions, including digestion of food and important 
regulatory functions for the enteric immune system.11,19,20 The production of short chain fatty acids as a 
byproduct of the fermentation of nondigestible carbohydrates by the gut microbiota has many uses, but 
one of them is the stimulation of T cell differentiation and modulating pro- and anti-inflammatory 
mechanisms.6 Low levels of SCFAs can contribute to inflammatory processes through a lack of adequate 
activation of anti-inflammatory mechanisms.20 
 
PI-IBS has also been discussed as a contributor to persistent inflammation in the GI tract, even 
after the resolution of the initial infection. The ongoing inflammation elicits an immune response, 
characterized by activation of immune cells and cytokines.5 
 
Psychosocial Factors & Brain-Gut Interactions 
 Serotonin is an integral regulator of GI function that is produced and released by 
enteroendocrine cells in the intestinal epithelium.5,6 It acts as a signaling molecule to neurons to target 
enterocytes, smooth muscle, and neurons to perform functions in secretions, peristalsis, and sensation. 
IBS has been associated with irregular serotonin signaling, leading to the GI symptoms that are 
commonly experienced by patients with IBS. The literature suggests that IBS-D patients have reduced 
serotonin reuptake, leading to increased circulating levels of serotonin,5 resulting in the overactive 
motility and visceral hypersensitivity that is characteristic of the disease.1  
 
 Altered serotonin signaling pathways also provide an explanation for the psychiatric 
abnormalities that are commonly seen as comorbidities with IBS. It is unclear in the literature whether it 
is abnormal serotonin levels that directly alter gut functioning and motility, or if altered serotonin leads 
to altered brain-gut interactions that increase visceral sensitivity and the feeling of ‘something being 
wrong’, but there is agreement that targeted therapies to address serotonin release and reuptake can 
improve symptoms.5 
 
Altered Gut Microbiota 
A growing area of research has highlighted the possibly of the gut microbiota as a major 
contributor to the pathogenesis of IBS. Dysbiosis is an alteration in the gut microbiota, characterized by 
an over- or underabundance of the typical classes of bacteria or archaea that typically inhabit the 
intestinal tract or other areas of the body.21 Commonly suggested factors in the pathogenesis of IBS 
include altered motility, inflammation, and altered gut epithelium permeability, all of which can be 
explained through dysbiosis in the gut microbiota of the small and large intestine. It is unclear whether it 
is an altered microbiota that specifically produce these enteric responses, but the research does show 
that patients with IBS tend to have a different microbiota than healthy controls.11,19–21  
 
Animal studies that address the gut microbiota typically use germ-free animals in their 
experimental designs. A germ-free animal is one that has been bred with an absence of microbes, and 
therefore has a sterile intestinal tract. The functional influence of differing microbe populations can be 
assessed by the transplantation of the gut microbiota from a host subject (human or animal) to the 
germ-free animal, typically through a fecal transplant method. Animal studies investigating the role of 
the microbiota in IBS have shown that a microbiota transplant to germ-free animals from patients with 
IBS results in visceral hypersensitivity, defects in the epithelial barrier, and altered colonic transit time, 
further suggesting that the microbiota plays a large role in the pathogenesis of IBS.6,19 
 
The high rate of development of IBS symptoms after enteric infections and/or after the use of 
antibiotics supports the hypothesis of an altered gut microbiota being a central cause of IBS, through to 
the alteration of the microbiota through infection or suppression by antibiotics.1,14,19,20   
 
A reduction in bacterial diversity in the small bowel in patients with IBS-D has been shown in the 
literature.22 The healthy GI tract typically has a population of microorganisms that gradually increase in 
concentration. The stomach and duodenum have the lowest concentration of microbes, at around 101 – 
103 cells per gram, and the colon has the highest concentration of bacteria at around 1011 – 1012 cells per 
gram.11 Bacteria can populate backwards from the colon through the ileocecal valve into the ileum and 
further into the small intestine, referred to as small intestinal bacterial overgrowth. 
 
Dysbiosis in the small bowel is often considered SIBO, with many SIBO patients also meeting 
diagnostic criteria for IBS-D. In one study of 567 patients that met criteria for upper GI endoscopy, 58.1% 
of the patients diagnosed with SIBO met Rome II criteria for IBS.22 Patients with IBS-D often have an 
excess concentration of Escherichia and Aeromonas species in the small bowel when compared to 
healthy controls, which is a shared colonization characteristic to patients with SIBO.22 It can be 
theorized, then, that many IBS patients may have SIBO, but SIBO is not a central cause of IBS symptoms, 
especially considering that IBS patients also experience dysbiosis of the colon.  
 
IBS patients commonly have a decrease in Bifidobacterium and Lactobacillus genera in the 
colon.11,19 These genera are considered beneficial, having roles in digestion, water reabsorption, 
regulation of the epithelial barrier, inflammation, immunity, and motility, so the alteration of these 
important microbe communities could lead to the development of IBS symptoms. Additionally, many 
probiotics are part of these genera, which will be discussed in a following section as a targeted 
treatment method. 
 
Members of the anaerobic Bifidobacterium and Lactobacillus genera are usually present in 
relatively small numbers compared to other bacteria that commonly populate the large intestine. The 
depletion of these anaerobic species may reduce the important production of SCFAs, as anaerobes are 
predominantly responsible for the digestion of fermentable carbohydrates. SCFA pathways include 
colonic salt and water reabsorption, suggesting that the symptoms of diarrhea and other IBS symptoms 
(including bloating, pain, and excess flatulence) may arise from this altered pathway.11 Gut bacteria also 
play a role in the integrity of the gut epithelium, through the creation of SCFAs which provide fuel for 
the epithelial cells of the gut. A decrease in SCFA production through a reduction in the prevalence of 
Bifidobacterium species may lead to an alteration in the tight junctions between epithelial cells. SCFAs 
also have roles in gut motility, inflammation, bile acid reabsorption, water and salt reabsorption in the 
colon, and gut immunity.6,19 Thus, a reduction in SCFA production can alter the homeostasis of these 
pathways and potentially lead to many of the commonly described etiological pathways of IBS.  
 
Lactobacillus appears to play roles in visceral pain sensation in animal studies, with a reduction 
in these bacterium inducing pain and sensitivity.11 Bifidobacterium also produce proteases, which are 
responsible for protein degradation in the gut prior to absorption. A reduced level of Bifidobacteria, as is 
seen in many IBS patients, may contribute to reduced protein degradation and the subsequent 
fermentation of protein products, which produce toxic byproducts that can harm the epithelial barrier 
and contribute to inflammation.6  
  
PHARMACOLOGIC TREATMENT METHODS 
 Pharmacologic treatment of IBS is a traditional method that addresses the symptoms that 
reduce quality of life in patients but does not have lasting effects on the underlying causes of IBS. The 
treatment methods discussed here may cause relief in the severity in symptoms, but do not cause 
lasting improvements upon discontinuation of the treatment. Medications used in an off-label fashion 
also carry other risks of side effects that are not related to IBS. 
 
Anti-Diarrheal Medications 
 Loperamide, known by the brand name Imodium, is an anti-diarrheal that is often used in the 
treatment of IBS-D. It has limited effects on other IBS symptoms, such as abdominal pain and bloating.23 
Loperamide functions by increasing transit time by slowing the contraction of intestinal muscle, allowing 
more time for water absorption.5 Though its risk of side effects are minimal due to loperamide not 
crossing the blood-brain barrier6, one major side effect is constipation if overused by IBS-D patients, or if 
used by patients with IBS-M (IBS with mixed diarrhea and constipation).1 
 
 Cholestyramine is a cholesterol-lowering medication that works by binding to bile acids in the 
intestine and preventing their absorption, inducing the liver to create bile by breaking down cholesterol 
in the body. However, it has been used in an off-label fashion to treat bile acid malabsorption-related 
diarrhea and has been used successfully in some IBS-D patients to reduce bowel movement frequency. 
The risk of constipation should be considered in the use of this drug, as well as the intended effects of 
reducing bile acid absorption and serum cholesterol.5 
 
Antidepressants and 5-HT3 Antagonists 
Antidepressants and serotonin receptor antagonists have been used in an off-label fashion to 
address the global IBS symptoms that, in part, result from the impaired serotonin signaling in IBS 
patients. Of the antidepressants, SSRIs (selective serotonin reuptake inhibitors) are not recommended 
for use in patients with IBS-D, as their mechanism of action increases the action of serotonin by blocking 
reuptake, which would exacerbate symptoms in IBS-D patients who already have an excess of circulating 
serotonin.7 TCAs (tricyclic antidepressants), rather, decrease bowel movement frequency and decrease 
the visceral hypersensitivity that leads to elevated pain in IBS-D patients.5,6 Side effect risks of TCAs 
include constipation, weight gain, and nausea. When using TCAs or SSRIs for IBS patients, it is 
recommended to begin at the lowest end of dosing and titrating upwards to find the lowest possible 
effective dose to avoid side effects and reduce psychological impact on the patient.7 
 
5-HT3 receptor antagonists are frequently used in IBS-D patients to reduce the mechanism of 
action of serotonin and to decrease diarrhea and abdominal pain. This class of drugs slows transit time 
and reduces visceral hypersensitivity.5,6 Alosetron, approved for women with IBS-D, is one such drug 
that is commonly a target of research studies due to its action of modulating visceral sensitivity through 
its interference with the serotonin receptor.5 It also slows motility and secretions in the colon, reducing 
the fluidity of bowel movements and thus reducing the frequency of diarrhea.1 The therapeutic effect on 
symptoms is approximately a 15% improvement over placebo.7 It has shown the most benefit in women 
with IBS-D, with the most common side effect being constipation, but more serious risks documented in 
the literature include ischemic colitis.6,8 Ondansetron is another 5-HT3 receptor antagonist that is less 
potent than alosetron, but may improve stool consistency, frequency, and pain, but not bloating.7 
 
Rifaximin 
 Rifaximin is a non-absorbable broad-spectrum antibiotic that was approved in 2015 for the 
treatment of IBS-D. It is unlike other traditional treatment methods in that the effects of treatment can 
last after discontinuation of the medication22, but is still a wide-lens approach to the treatment of IBS. 
The modulation of the gut microbiota by rifaximin is one of the proposed mechanisms of action of the 
antibiotic. A downstream effect is the reduction of inflammation through reduction in pro-inflammatory 
bacteria and a reduction of immune response through inhibition of bacteria-host interactions. 
 
Rifaximin is commonly used in patients with SIBO that also meet diagnostic criteria for IBS-D as 
it is effective to reduce the species that are typically increased in SIBO, such as Escherichia coli, 
Enterobacter, and Enterococcus faecalis.22 The effects of rifaximin on IBS symptoms has been 
documented in many studies. The TARGET 1 and TARGET 2 trials evaluated the long-term success rate of 
rifaximin on reducing IBS symptoms, finding global IBS symptom reduction rates ranging from 40.7% to 
42.2% with continued symptom improvement after culmination of the course of treatment, but the 
post-study observation only lasted 12-14 weeks.22 In another study with patients with so-called SIBO-
related IBS (confirmed by breath test and positive diagnosis using Rome criteria), a 14-day course of 
rifaximin resulted in 83-86% of patients having a negative follow-up breath test22, suggesting that 
rifaximin is effective at treating symptom-inducing dysbiosis in the small intestine.  
 
 The use of rifaximin is a nontargeted approach to treat IBS, SIBO, and other GI disorders due to 
the wide-ranging effects on the microbiota. Its efficacy in treating IBS, specifically, is still undergoing trial 
testing. Symptom reoccurrence after the use of rifaximin has been documented in the literature. Lembo, 
et al, conducted a study that evaluated the efficacy and safety of repeat courses of rifaximin treatment 
in patients with IBS-D.23 After a single course of rifaximin treatment, 64.4% (692 of 1074 responders to 
the antibiotic) experienced a relapse in symptoms over a maximum of 18 weeks. Patients who 
experienced a relapse in symptoms then underwent a second course of rifaximin, with 38.1% 
responding to repeat treatment (compared to 31.5% of patients responding to placebo, p=0.03). For 
specific symptom relief, a statistically significant response was seen in abdominal pain (50.6% vs 42.2%, 
p=0.018) but not in bowel movement consistency (51.8% vs 50.0%, p=0.42). A third treatment course 
with rifaximin was used in all patients who met criteria for the second course, to evaluate the safety of 
repeat treatments with the antibiotic.23 Adverse events were rare, and serious side effects (experienced 
by 4 patients in each treatment group) were concluded to be unrelated to the study. The takeaway from 
this study is that repeat courses of rifaximin are safe in patients with IBS-D, and may be effective in 
reducing symptoms, but relapse in IBS symptoms is likely.  
 
Though the efficacy of rifaximin in improving IBS symptoms, including pain, bloating, and stool 
consistency, has been documented in several clinical trials, the use of rifaximin is one approach to IBS 
symptom management but is not a long-term solution to increase quality of life in patients. There is not 
a consensus on its true mechanism of action, whether it is treating small intestinal bacterial overgrowth 
or altering the microbiota in the large intestine.5 Rifaximin may also confound the effects of other 
simultaneous treatments that are more targeted approaches. Thus, it is not currently recommended to 
use rifaximin as a first-line intervention, but instead to only utilize antibiotic treatments in IBS patients 
without constipation that have failed other treatment attempts.1,5 
 
TARGETED TREATMENT METHODS 
Pharmacologic interventions for IBS manage the symptoms, rather than the pathophysiology of 
the disease. However, more targeted treatment methods have begun to address the underlying etiology 
of the symptoms to produce better outcomes.5 Using lifestyle and environmental approaches is a more 
targeted solution to create long-term relief and hopefully lead to remission of symptoms.  
 
Prebiotics and Probiotics 
 Patients with IBS-D specifically have been characterized in the literature with a decreased 
concentration of Lactobacillus and Bifidobacterium.27 Recent research has explored the treatment of IBS 
with pre- and probiotics, attempting to restore healthy microbiota concentration in order to improve 
symptoms of IBS. Prebiotics are nutrients that provide fuel to the microbiota while probiotics are live 
strains of microorganisms. Synbiotics are a combination treatment of pre- and probiotics that work 
synergistically together.19 Products of carbohydrate digestion by the microbiota have effects on the 
contractility of the intestine and can affect motility and visceral sensitivity. A targeted increase in 
Bifidobacterium, Lactobacillus, and Veillonella species in patients with IBS have been shown to result in 
increased production of SCFAs27, which improves epithelial tight junctions, motility, inflammation, and 
immunity.  
 
Probiotics, when taken properly, can improve the integrity of the epithelial barrier, promote 
better tolerance of foods, prevent pathogenic adhesion to the gut mucosa and thus reduce 
inflammation, modulate immune responses, and reduce symptoms of GI distress by promoting proper 
digestion.28 A systematic review in 2008 evaluated the efficacy of probiotics in treating symptoms of IBS, 
finding no difference between individual strains used (Bifidobacterium, Lactobacillus, Streptococcus, and 
combinations of these genera) but found that all trials showed a beneficial effect on the severity of IBS 
symptoms.21 However, it is important to consider the individual actions of each specific strain of 
bacteria, in order to target the symptoms present in each patient.21 Thus, patients with IBS-D should be 
treated differently than those with IBS-C, as bacterial strains have different effects and could either 
worsen or improve symptoms, depending on the subtype of IBS. 
 
Prebiotics are carbohydrates that are poorly digested in the small intestine and are fermented 
by the colonic microbiota. Prebiotics in the diet promote production of metabolic end-products, namely 
SCFAs, that then have a variety of beneficial effects. It should be considered that many prebiotics are 
FODMAP foods, so the FODMAP diet restricts much of the fuel for the beneficial intestinal microbiota 
that probiotics are supplementing.29 Some early research has indicated that a diet low in FODMAPs may 
further decrease concentrations of healthy microbiota, especially Bifidobacterium6, so combination of 
exclusion diets with probiotic supplements is an area of research that may further clarify this 
relationship. 
 
Over-the-counter probiotic strains commonly contain a variety of species in the Bifidobacterium 
and Lactobacillus genera, both of which have been extensively studied and shown to reduce 
inflammation, bloating, diarrhea, and abdominal pain.11,21 While the dosing amounts and specific species 
considerations of probiotic use are outside the scope of this review, the conclusion to be taken from this 
is that the use of probiotics can be beneficial for IBS patients, either in isolation or in combination with 
other targeted treatment modalities that address dysbiosis, one of the major underlying causes of IBS. 
 
Fecal Microbiota Transplants 
 Fecal microbiota transplant (FMT) is one treatment method that has received more attention in 
research and the media. FMT is used to modulate the gut microbiota and restore proper balance to the 
concentration of healthy bacteria through the transplantation of microbiota samples from a healthy 
donor to the patient. FMT is currently used as a curative treatment for CDI and is being further explored 
in research trials for its potential use in FGIDs.27 
 
 FMT donors should be carefully screened and selected. Though FMT in IBS patients is still 
undergoing trials, a systematic review found that outcomes were slightly better in patients with CDI who 
received FMT from closely related donors, such as spouses or first-degree relatives.27 Donors, whether 
for CDI or IBS-related transplants, should be screened for recent C. diff infection, any antibiotic use in 
the prior three months, immunosuppression medications, drug use, recent incarceration, recent travel 
to areas known for diarrheal illnesses, metabolic syndrome or diabetes, or any history of IBD, IBS, or GI 
malignancy.27 
 
 One trial by Borody, et al, in 1989, before the large increase in research on microbiota and FMT 
occurred, administered FMT to 55 patients with IBS and IBD. The study followed the subjects for 1-12 
months, finding a 36% (20/55 patients) cure rate, 16% (9/55) with symptom relief but not total 
remission, and 47% (26/55) with no change in symptoms.27,30 One limitation of this trial is that the 
results did not differentiate between patients with IBS and IBD.  
 
 A more recent clinical trial by Pinn, et al, in 2015, claiming to be the first randomized trial on 
FMT in IBS patients, found that FMT was more effective than placebo in decreasing symptom severity in 
patients with IBS-D or IBS-M at three months post-transplant, but not at 12 months. This study found 
that 65% of participants receiving the treatment had a decrease in symptom severity, while only 43% of 
placebo recipients showed the same change (p=0.049).24  
 
 A systematic review by Halkjaer, et al, compiled results from these two studies as well as seven 
others. The meta-analysis, after exclusions, was comprised of 48 patients, of whom 58% experienced 
symptom improvement after FMT with no serious side effects.30 
 
 The route of FMT administration needs to be further studied to determine the most efficient 
and effective way to deliver the FMT to IBS patients.27,30 Since IBS affects the whole GI tract and not just 
the colon, it is reasonable to consider that NG tube or EGD delivery may be more effective than 
colonoscopy or enema administration, since it may modulate the microbiota of the small intestine in 
addition to the colon.  
 
The temporal relationship between FMT and IBS symptom relief is another factor that requires 
further study; using knowledge from the treatment of CDI, FMT can take several months to show effect, 
during which time the modulation of the microbiota is sensitive and can be affected by other 
environmental factors.30 CDI infections have been shown to have higher cure rates with repeat FMT 
from different donors, suggesting that IBS may be similarly treated with one or more FMT over a period 
of time, to increase the effectiveness of the beneficial shift in the microbiota.24 
 
Gluten Restriction 
Gluten restriction is used by some patients that experience a reduction in symptoms when 
gluten is excluded from the diet. While this may be one way to improve quality of life and reduce the 
severity of the disease, this is not a treatment method that addresses the underlying cause of 
symptoms. Since NCGS is a food sensitivity and does not have immune or inflammatory responses 
within the GI tract, it cannot explain the reason for the symptoms of IBS and cannot be considered a 
‘curative’ treatment.  
 
Another explanation for the reduction in symptoms that occur when gluten is excluded is that 
wheat-based foods, such as pasta and bread, contain fructans, which, as described below, is a 
fermentable carbohydrate and can increase the production of gas and lead to bloating and pain.6,7 These 
foods in large quantities can elicit a symptomatic response through the fermentation of the 
carbohydrates. This is a reaction to the carbohydrates, however, and not the gluten protein, so cannot 




The FODMAP Diet 
FODMAP is an acronym for fermentable oligo-, di-, and monosaccharides and polyols. It is a diet 
that has gained more attention over the recent decade as being effective for the reduction of GI 
symptoms in IBS patients, and occasionally for IBD, due to these fermentable carbohydrates being 
digested by gut bacteria to create gas which can lead to excess bloating. The FODMAP diet has shown 
success in reducing symptoms in IBS patients, but it is difficult to test in clinical trials due to the complex 
nature of creating a control group or placebo in randomized trials.1 As FODMAP restriction has been 
shown in the literature to reduce the symptoms of IBS, it can be hypothesized that the excessive 
fermentation of FODMAPs by an altered gut microbiota is an evidence for the strong role of dysbiosis in 
IBS.24,25 Some patients, especially those with dysbiosis, may symptomatically respond to a diet low in 
FODMAPs.1,25 Many foods that are restricted on the FODMAP diet are actually prebiotics, or foods that 
provide fuel for the microbiota. These foods, or the restriction of them, can theoretically alter the 
microbiota but more research is needed on the direct impact on FODMAPs on the microbiota.11  
 
The FODMAP diet is a three-phase diet plan that eliminates all fermentable carbohydrates 
(Figure 5) from a patient’s diet and then reintroduces them to determine the patient’s unique, individual 
response to specific fermentable carbohydrates. Prior to beginning the elimination diet, the patient 
should meet with a registered dietitian to discuss typical eating habits, lifestyle, and address any 
challenges to beginning such a restrictive diet, such as financial or logistical factors. They should 
consider challenges, such as dining out, attending meals at friend’s or family’s homes, and preparing 
food for others. Finally, they should understand the importance of keeping careful records of symptoms 
throughout this process and be committed to adhering to the recommendations, for the purpose of 
gleaning the most benefit from the FODMAP diet plan.  
 
The first stage is the elimination phase, in which the patient eliminates all foods from the 
FODMAP list from their diet and maintains this strict diet for six to eight weeks.25 The second stage is a 
gradual reintroduction phase, when patients slowly and methodically reintroduce FODMAP foods into 
their diet and keep careful records of symptomatic responses. Finally, the final stage is a maintenance 
phase, when the patient and their dietitian have identified their individual triggers and avoid these 
foods as a long-term, less restrictive diet plan to help control their IBS symptoms.26  
 
The reintroduction phase should be carefully executed, with close management by a registered 
dietitian who is knowledgeable on the FODMAP diet. It is recommended to reintroduce foods one at a 
time, in small amounts and in isolation of other FODMAP-containing foods, in order to determine 
specific triggers to GI symptoms. By isolating individual triggers, the long-term outcome can be 
improved by reducing the restrictive nature of the diet as much as possible and reducing the risk of 















fennel, garlic, leeks, 
okra, onions, peas, 
shallots 
Fruits: watermelon, 
custard apple, white 
peaches, rambutan, 
persimmon 
Cereals: wheat and rye (in 




lentils, kidney beans, 
baked beans 
Cow milk, goat milk, and 
sheep milk, and 
products made from it 




Soft and fresh cheeses 
(ricotta, cottage) 
Vegetables: asparagus, 
artichokes, sugar snap 
peas 
Fruits: apples, pears, 
nashi pears, clingstone 
peaches, mango, sugar 
snap peas, watermelon, 







sources (such as fruit 
juice), large servings of 
fruit, dried fruit 
Vegetables: avocado, 
cauliflower, 
mushrooms, snow peas 
Fruits: apples, apricots, 
cherries, lychee, nashi 
pears, nectarines, 




maltitol, isomalt, and 
others ending in -ol 
Figure 5. A list of FODMAP-containing foods to be excluded in the first phase of the FODMAP diet. 
 
OUTCOMES AND IMPLICATIONS FOR CLINICAL DIETETIC PRACTICE 
 Clinical implications of the proposed mechanisms of pathogenesis of IBS and the associated 
treatment methods should be considered prior to developing a care plan for the patient. It is an 
important note that there is currently no validated method to evaluating the makeup of the gut 
microbiota of the patient11, and thus the targeted treatment methods of IBS through diet, probiotics, or 
fecal transplants are still in early phases. Dietitians and other health care providers that encounter IBS-D 
should keep a holistic view of the patient, considering not just GI symptoms but the underlying causes. 
 
The use of carefully tailored exclusion diets, probiotics, and FMT address the underlying causes 
of IBS rather than only controlling the symptoms. Modulating the gut microbiota is an approach that can 
have impacts on symptoms and quality of life in patients with IBS and can lead to lasting relief and 
improvements in quality of life. The composition of the microbiota seems to be the underlying concern 
in the treatment of IBS-D, and manipulation of the concentration of specific genera and careful 
attention to the diet can lead to large improvements in symptoms of IBS. As discussed by Simren, et al, it 
appears that probiotic supplementation directly affects the composition of the gut microbiota while the 
FODMAP diet affects the interaction between the gut microbiota and foods.29  
 
One recent randomized, double-blind study compared the use of a prebiotic supplement with a 
placebo diet (Mediterranean-like) against a placebo supplement with the FODMAP diet and evaluated 
the composition of the gut microbiota, as well as gas production and abdominal pain.31 They found that 
the prebiotic group had an increase in the beneficial Bifidobacterium. Additionally, while both groups 
showed an initial improvement in IBS symptoms, the symptoms immediately returned when patients 
discontinued the FODMAP diet, while the prebiotic group had symptom relief that lasted for two weeks 
after the discontinuation of supplementation.31 The implications of this trial are that the FODMAP diet, 
as a heavily restrictive diet, may not have beneficial long-term outcomes, and instead a less restrictive 
diet with the combination of pre- or probiotic supplementation may be more effective in treating the 
symptoms of IBS.  
 
 While restrictive diets are never the goal of treatment when a dietitian counsels a patient, as 
they can lead to a poor relationship with food and possible disordered eating behaviors, following an 
individually tailored diet plan that has been formulated with the help of a registered dietitian can help to 
improve the patient’s quality of life. By only excluding the foods that exacerbate symptoms, the patient 
can have an overall better relationship with food with less overall food avoidance and more enjoyment 
of social eating occasions. 
 
The long-term effects of treatment on symptom relief is an area of research that needs further 
attention, with the development of well-designed clinical trials with proper control groups and a long-
term follow up. Areas to be addressed include specific species of probiotics, the effect of diet and 
probiotics on the intestinal microbiota, and the temporal relationship between treatment modalities 
and symptomatic relief. In an effort to improve the quality of life of patients with IBS-D, the rigor of the 
treatment method as well as the outcomes should be considered in conjunction with each other, to 
determine the least invasive treatment method with the best possible long-term outcome.  
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